Company
Tivic Health
Valion Bio is a clinical-stage immunotherapeutics company advancing Entolimod, a TLR5 agonist, being developed to protect against radiation injury and to support immune function in oncology settings.
Also known as Tivic Health Systems Inc., Valion Bio
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Legal name
- Tivic Health Systems Inc.
Claim, correct or request removal
Record updated 28 September 2026
About
Valion Bio (Nasdaq: VBIO) is developing Entolimod, a Toll-like Receptor 5 agonist that activates the innate immune system — the body’s first line of defense against radiation injury, infection, and cellular stress.
Funding snapshot
- Total raised
- $36.2MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $12M2025-12-10
Funding rounds
- Round, 2025
- $12M2025-12-10, SEC form D sold, 5 investors
- Round, 2025
- $16.3M2025-12-10, SEC form D sold, 1 investor
- Round, 2019
- $7.9M2019-07-16, SEC form D sold, 66 investors
Products
- Other
- Entolimod
Loading relationship preview